Oct 22 (Reuters) - Eurofins Scientific SE EUFI.PA :
* CONFIRMS PROFITABILITY AND CASH FLOW OBJECTIVES FOR 2024
LEADING
TO HIGHER PROFIT MARGINS IN SPITE OF THE IMPACT OF THE
POST-COVID RESET OF BIOPHARMA PIPELINES
* REPORTED REVENUES IN 9M 2024 REACHED EUR 5,142M, +6.7%
VERSUS 9M
2023
* CORE BUSINESS ORGANIC REVENUE GROWTH 5.2% IN 9M 2024
* UPDATES FY 2024 OBJECTIVES
* OBJECTIVES FOR FY 2024, ANNOUNCED AT FY 2023 RESULTS
PRESENTATION ON 27 FEBRUARY 2024, HAVE BEEN PARTLY UPDATED
* EXPECTS FY 2024 ADJUSTED EBITDA OF €1.525BN-€1.575BN
* OUTLOOK 2024 REVENUE CLOSE TO EUR 7 BILLION
* EXPECTS FY 2024 FCFF OF €800M-€840M
* TARGETS FINANCIAL LEVERAGE OF 1.5-2.5X IN MID-TERM
* OUTLOOK: OBJECTIVES FOR FY 2027, ANNOUNCED ON 1 MARCH
2023,
REMAIN UNCHANGED
* ON ACQUISITION OF SGS' CROP SCIENCE OPERATIONS: COMMITTED
TO
FOLLOWING THROUGH WITH TRANSACTION
Source text for Workspace: ID:nBw73cXkQa
Further company coverage: EUFI.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))